bioAffinity Technologies, Inc. (BIAF) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

bioAffinity Technologies, Inc. (BIAF) closed at USD 3.96 on 2026-10-15, a change of -89.4 % over the past year, with a market capitalization of USD 4.79M.

bioAffinity Technologies, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

bioAffinity Technologies, Inc. key figures

Previous close

USD 3.96 (2026-10-15)

1-year change

-89.4 %

Market cap

USD 4.79M

Enterprise value

USD 1.02M

P/E ratio (trailing)

-0.03

P/E ratio (forward)

-6.22

EPS (trailing)

-109.35

EPS (forward)

-0.60

PEG ratio

n/a

Price to book

0.45

Revenue growth

19 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.01

Employees

57

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for bioAffinity Technologies, Inc. and compare it with other stocks.